Sign in

You're signed outSign in or to get full access.

BB

Barinthus Biotherapeutics plc. (BRNS)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 results were driven by a full-year revenue of $15.0M recognized primarily in Q3 from OUI royalty receipts (AstraZeneca’s Vaxzevria), with Q4 revenue effectively $0; EPS for Q4 was an S&P Global actual of $(0.20) versus a consensus of $(0.41), a significant beat driven by lower operating loss than expected and the absence of additional revenue recognition in Q4 *.
  • Management pivoted to immunology and inflammation, prioritizing VTP-1000 in celiac disease and seeking partners for VTP-300; cost actions and UK site reduction extended cash runway into 2027, improving from Q3’s guidance into Q2 2026 .
  • Clinical catalysts in 2025: HBV003 and IM-PROVE II topline results in Q2 2025; VTP-850 Phase 1 data in Q2 2025; VTP-1000 Phase 1 SAD data now expected in Q3 2025 (timing shift later than prior guidance) .
  • Notable one-time items: $12.2M goodwill impairment in Q4/FY 2024, with FY net loss of $61.1M ($(1.55) per share), and a strategic restructuring reducing headcount ~65% to concentrate operations in the U.S. .

What Went Well and What Went Wrong

What Went Well

  • “We’ve entered 2025 with a refreshed strategic focus on immunological and inflammatory diseases… VTP-1000 has promise to be a leading therapy for the approximate 80 million people worldwide with celiac disease,” CEO Bill Enright highlighted the SNAP-TI platform’s differentiation and potential pipeline leverage .
  • HBV program showed the most encouraging clinical data to date: HBV003 interim results include eight HBsAg losses and two functional cures, with evidence of HBsAb seroconversion; IM-PROVE II Group C (imdusiran + VTP-300 + low-dose nivolumab) had statistically greater HBsAg declines and 23% HBsAg loss at Week 48 .
  • Cash runway extended to 2027 through restructuring and prioritization; FY 2024 revenue boosted by $15.0M royalty-related license revenue, supporting liquidity and program focus .

What Went Wrong

  • Timing slippage: VTP-1000 Phase 1 SAD data moved from “H1 2025” (Q3 guidance) to “Q3 2025,” delaying clinical readout in the lead I&I asset .
  • One-time non-cash impact: $12.2M goodwill impairment in Q4/FY 2024 increased reported operating loss; underscores asset utilization reassessment amid strategic refocus .
  • Workforce reduction (~65%) and anticipated UK site closure—necessary for runway extension but introduces execution risk and transition complexities; partnering needed to advance VTP-300 beyond HBV003 .

Financial Results

Revenue, EPS, Net Loss – Quarterly (oldest → newest)

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$0.0 $14.97 $0.0*
EPS ($USD)$(0.43) $(0.21) $(0.20)*
Net Loss ($USD Millions)$(16.93) $(8.11) N/A

Values with asterisks retrieved from S&P Global.

Notes: Q3 revenue reflects $14.969M license revenue recognized from OUI royalty; Q4 revenue effectively zero, consistent with company disclosure of no expectation of additional payments .

Q4 2024 vs Wall Street Consensus (S&P Global)

MetricConsensusActualBeat/Miss
EPS ($USD)$(0.41)*$(0.20)*Beat by $0.21
Revenue ($USD Millions)$0.0*$0.0*In line

Values retrieved from S&P Global.

Liquidity KPIs

MetricJun 30, 2024Sep 30, 2024Dec 31, 2024
Cash, Cash Equivalents & Restricted Cash ($USD Millions)$117.8 $106.1 $112.4

FY 2024 Summary (context)

MetricFY 2023FY 2024
Revenue ($USD Millions)$0.8 $15.0
R&D Expense ($USD Millions)$44.9 $42.2
G&A Expense ($USD Millions)$39.8 $29.7
Goodwill Impairment ($USD Millions)$0.0 $12.2
Net Loss ($USD Millions)$(73.3) $(61.1)
EPS ($USD)$(1.91) $(1.55)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash runwayCorporateInto Q2 2026 Into 2027 Raised/Extended
VTP-1000 Phase 1 SAD readoutCeliacH1 2025 Q3 2025 Lowered/Delayed
VTP-1000 Phase 1 MAD initiationCeliacN/AH2 2025 New
HBV003 toplineHBVQ4 2024 interim at AASLD Q2 2025 topline Maintained (next stage timing)
IM-PROVE II toplineHBVQ4 2024 interim at AASLD Q2 2025 topline Maintained (next stage timing)
VTP-850 Phase 1 dataProstateH1 2025 Q2 2025 Maintained/Specified
HBV investment postureHBVPrioritized HBV in 2024 No further investment beyond HBV003; seek partner Lowered/Partnering

Earnings Call Themes & Trends

Transcript content was not available in our document set; company reported call timing around Q4/FY release . We track themes from Q2–Q4 2024 releases and the January 2025 strategic update.

TopicQ2 2024 (Aug)Q3 2024 (Nov)Q4 2024 / Jan 2025
Strategic focusPrioritized HBV & celiac; early workforce reduction Clinical execution; data-rich Q4 expected Refocus to I&I; partner HBV; 65% workforce reduction; US-centric ops
Cash runwayInto Q2 2026 Into Q2 2026 (post $15M revenue) Into 2027 (post restructuring)
VTP-1000 (SNAP-TI)First-in-human planned Q3 2024 AVALON initiated; SAD data H1 2025 SAD data in Q3 2025; MAD in H2 2025
HBV (VTP-300 ± PD‑1/siRNA)Interim data at EASL showed robust declines AASLD interim: HBsAg loss, functional cure, HBsAb seroconversion Q2 2025 topline expected; partnering pursued
Restructuring/opsPipeline prioritization; new CMO —65% headcount reduction; UK site closure anticipated
FX and G&AFX gain Q2; G&A $7.2M FX loss increased G&A to $13.4M FY G&A $29.7M; FX gain $2.4M

Trend: Narrative shifted decisively to I&I with SNAP-TI leadership, de-risking cash runway via restructuring and pushing for external HBV partnerships, while maintaining near-term clinical catalysts.

Management Commentary

  • “VTP-1000… has promise to be a leading therapy for the approximate 80 million people worldwide with celiac disease… we believe SNAP-TI is poised to drive multiple future pipeline and partnership opportunities,” — Bill Enright, CEO .
  • “Entering 2025, we have decided to focus on broadening the potential of our SNAP-TI platform to address autoimmune diseases… we have made the difficult decision to reduce our presence in the U.K. significantly and to reduce our workforce,” — Bill Enright, CEO .
  • On HBV: “These Phase 2 data are incredibly encouraging and highlight the ability of VTP-300 to stimulate the immune response and induce sustained reductions in HBsAg to the point of meeting functional cure criteria,” — Dr. Nadège Pelletier, CSO (at the time) .

Q&A Highlights

  • An earnings call transcript for Q4/FY 2024 was not found in our document corpus; company materials indicate the call occurred around March 19–20, 2025 .
  • Guidance clarifications from press releases: VTP-1000 SAD timing moved to Q3 2025; HBV toplines targeted for Q2 2025; runway into 2027 affirmed post-restructuring .

Estimates Context

  • Q4 2024 EPS beat: Actual $(0.20)* vs consensus $(0.41); magnitude suggests lower-than-feared operating loss and no incremental revenue recognition in Q4 .
  • Revenue in line with consensus at $0.0*; the company stated no expectation of additional OUI royalty payments, consistent with Q4 revenue outcome *.
  • Consensus depth: 3 EPS estimates and 3 revenue estimates for Q4 2024, indicating modest street coverage; outlook likely to recalibrate around I&I focus and HBV partnering [GetEstimates]*.

Values retrieved from S&P Global.

Key Takeaways for Investors

  • The pivot to I&I and SNAP-TI centrality increases strategic coherence and may command higher-quality partnership optionality; near-term data from VTP-1000 (Q3 2025) and HBV combinations (Q2 2025) are key stock catalysts .
  • Cash runway extended into 2027 mitigates financing risk; restructuring and UK footprint reduction lower run-rate but elevate execution risk during transition .
  • HBV readouts are clinically meaningful (HBsAg loss, functional cure signals, HBsAb seroconversion) but capital-light progression depends on partnering; monitor announced toplines and deal activity in H1 2025 .
  • VTP-1000 timing delay from H1 to Q3 2025 resets expectations; the MAD portion with gluten challenge in H2 2025 could provide early efficacy proxies relevant for valuation inflection .
  • FY 2024 one-time goodwill impairment ($12.2M) and restructuring charges (est. ~$2.5M) complicate near-term P&L optics; underlying Opex trending lower than FY 2023 supports runway claims .
  • Trading setup: EPS beat vs consensus and 2027 runway are supportive, but the absence of revenue growth drivers until clinical catalysts mature suggests binary event risk concentration in Q2–Q3 2025; consider position sizing around data windows *.
  • Medium-term thesis: If SNAP-TI demonstrates robust human signals in celiac and HBV partnering de-risks development costs, a focused I&I platform could warrant re-rating; execution on partnering and credible SAD/MAD readouts are pivotal .

S&P Global estimates disclaimer: Values marked with an asterisk (*) are retrieved from S&P Global.